secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2026-09-23T10:03:20+00:00
Accession:  0001140361-26-037371
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis and Roche report positive Phase 3 interim data for sefaxersen in IgAN
---------------------------------------------------------------------------

- Phase 3 IMAgINATION met primary endpoint: sefaxersen reduced proteinuria (UPCR) vs placebo at 37 weeks, statistically significant and clinically meaningful.
- Safety consistent with prior data, no new signals; study continues blinded to week 105 eGFR assessment.
- 459 patients enrolled, randomized 1:1; sefaxersen is once-monthly subcutaneous self-administered injection.
- Interim data to be presented at medical meeting and shared with health authorities to expedite potential approval.
- Ionis eligible for regulatory/sales milestones and tiered royalties on net sales from Roche license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/0001140361-26-037371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036126037371/ef20082626_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-037371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer